{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:48:56Z","timestamp":1792252136164,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":284,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101485","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:51:42Z","timestamp":1792237902000},"page":"101485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical response rates and adverse events associated with therapeutic tumor vaccines in lymphoma: A systematic review"],"prefix":"10.1016","volume":"49","author":[{"given":"Alireza","family":"Ghasemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0250-5714","authenticated-orcid":false,"given":"Mohammadreza","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saghar","family":"Hoseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Samareh","family":"Salavatipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Tavoosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Baghsheikhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-0460","authenticated-orcid":false,"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-3290","authenticated-orcid":false,"given":"Mahshid Akhavan","family":"Rahnama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101485_bib0001","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0000000000000451","article-title":"Lymphoma classification","volume":"26","author":"de Leval","year":"2020","journal-title":"Cancer J."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101485_bib0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101485_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00277-026-06790-y","article-title":"Global, regional, and national patterns of change in the burden of Hodgkin lymphoma from 1990 to 2021: an analysis of the global burden of disease study 2021 and projections to 2035","volume":"105","author":"Pu","year":"2026","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101485_bib0004","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1007\/s00277-025-06559-9","article-title":"The global, regional, and national burden of non-Hodgkin lymphoma in 204 countries and territories and 811 subnational locations, 1990-2021: an update from the Global Burden of Disease Study 2021","volume":"104","author":"Li","year":"2025","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101485_bib0005","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1515\/jtim-2025-0025","article-title":"Comprehensive investigation of cuproptosis-related genes in clinical features, biological characteristics, and immune microenvironment in B-cell Non-Hodgkin lymphoma","volume":"13","author":"Liu","year":"2025","journal-title":"J. Transl. Int. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101485_bib0006","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1097\/JS9.0000000000003988","article-title":"Chimeric antigen receptor T-cell therapy in patients with lymphoma: a machine learning-driven decadal informatics network analysis","volume":"112","author":"Guo","year":"2026","journal-title":"Int. J. Surg."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101485_bib0007","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J."},{"issue":"7378","key":"10.1016\/j.ctarc.2026.101485_bib0008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101485_bib0009","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/ph16101384","article-title":"Tumor vaccines: unleashing the power of the immune system to fight cancer","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101485_bib0010","article-title":"A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma","volume":"11","author":"Tojjari","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101485_bib0011","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.3390\/cancers15174265","article-title":"Advances in immunotherapeutics in pancreatic ductal adenocarcinoma","volume":"15","author":"Chouari","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101485_bib0012","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/08830185.2022.2101647","article-title":"Combinatorial approaches to effective therapy in glioblastoma (GBM): current status and what the future holds","volume":"41","author":"Asija","year":"2022","journal-title":"Int. Rev. Immunol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101485_bib0013","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1182\/bloodadvances.2022007792","article-title":"Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma","volume":"8","author":"Ramirez","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ctarc.2026.101485_bib0014","first-page":"209","article-title":"Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study","volume":"26","author":"Ovali","year":"2007","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101485_bib0015","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/10428190500376365","article-title":"Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies","volume":"47","author":"Ritchie","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ctarc.2026.101485_bib0016","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101485_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002240","article-title":"Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells","volume":"9","author":"Fuca","year":"2021","journal-title":"J. ImmunOther Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101485_bib0018","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191712","article-title":"Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: a phase I\/II trial","volume":"217","author":"Frank","year":"2020","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101485_bib0019","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.bbmt.2016.08.028","article-title":"Induction of immune response after allogeneic Wilms' Tumor 1 dendritic cell vaccination and donor lymphocyte infusion in patients with hematologic malignancies and post-transplantation relapse","volume":"22","author":"Shah","year":"2016","journal-title":"Biol. Blood Marrow TransPl."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101485_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcyt.2015.09.012","article-title":"Combination of cytokine-induced killer and dendritic cells pulsed with antigenic alpha-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy","volume":"18","author":"Qiu","year":"2016","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101485_bib0021","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2014-07-592162","article-title":"Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma","volume":"125","author":"Kolstad","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101485_bib0022","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active idiotypic vaccination versus control immunotherapy for follicular lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101485_bib0023","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2010-06-292342","article-title":"Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma","volume":"117","author":"Navarrete","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101485_bib0024","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbmt.2011.06.011","article-title":"Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"18","author":"Holman","year":"2012","journal-title":"Biol. Blood Marrow TransPl."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101485_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/10428190802601122","article-title":"Prolonged idiotypic vaccination against follicular lymphoma","volume":"50","author":"Inoges","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101485_bib0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cncr.22389","article-title":"Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101485_bib0027","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2005.04.4289","article-title":"Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses","volume":"24","author":"Redfern","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101485_bib0028","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1158\/1078-0432.CCR-04-1071","article-title":"Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen","volume":"10","author":"Neelapu","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101485_bib0029","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101485_bib0030","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101485_bib0031","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101485_bib0032","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101485_bib0033","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/vaccines14060473","article-title":"Therapeutic cancer vaccines in B-cell malignancies and multiple myeloma","volume":"14","author":"Shah","year":"2026","journal-title":"Vaccines."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101485_bib0034","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/cells12172147","article-title":"Dendritic cell vaccines: a shift from conventional approach to new generations","volume":"12","author":"Lee","year":"2023","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101485_bib0035","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1080\/10428194.2020.1805113","article-title":"Therapeutic vaccines for aggressive B-cell lymphoma","volume":"61","author":"Xu-Monette","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101485_bib0036","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/ph17030272","article-title":"Therapeutic vaccines for follicular lymphoma: a systematic review","volume":"17","author":"Suponin","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101485_bib0037","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hon.2875","article-title":"Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: a systematic review and meta-analysis","volume":"39","author":"Bastin","year":"2021","journal-title":"Hematol. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:15:48Z","timestamp":1792250148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"alternative-id":["S2468294226003941"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101485","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical response rates and adverse events associated with therapeutic tumor vaccines in lymphoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101485"}}